Progress and problems with the use of suicide genes for targeted cancer therapy

Area of Science:

• Oncology
• Gene Therapy
• Biochemistry

Background:

• Suicide gene therapy offers targeted cancer treatment by activating prodrugs within tumor cells.
• This approach aims to enhance the therapeutic index by concentrating cytotoxic agents at the tumor site.
• Despite preclinical success, clinical translation of cancer suicide gene therapy remains a challenge.

Purpose of the Study:

• To critically review the six primary enzyme/prodrug systems used in cancer suicide gene therapy.
• To present the current state-of-the-art research and clinical practices in the field.
• To identify limitations and areas for improvement to achieve clinical significance.

Main Methods:

• Discussion of mechanisms of action for each enzyme/prodrug system.
• Analysis of protein engineering and prodrug modification strategies.
• Review of major clinical trials conducted over the past decade.

Main Results:

• Detailed examination of six key enzyme/prodrug systems in cancer suicide gene therapy.
• Evaluation of advancements in enzyme stability, prodrug potency, and clinical trial outcomes.
• Identification of specific challenges hindering clinical efficacy.

Conclusions:

• Cancer suicide gene therapy demonstrates significant preclinical potential but has not yet achieved widespread clinical success.
• Improvements in enzyme/prodrug systems and clinical trial design are crucial for future therapeutic applications.
• Further research is needed to overcome existing limitations and translate this therapy into effective clinical treatments.